Dr. Robyn Domsic
Rheumatology (Rheumatology Physician)
3601 5th Ave, Suite 2b Falk Medical Building
Pittsburgh, PA 15213
- Medicare participating
At a glance
- Medical school
- University of Iowa, Rj & L Carver College of Medicine (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 66
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Iowa, Rj & L Carver College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
PA license MD426216
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- UPMC Presbyterian Shadyside Pittsburgh, PA
- Magee Womens Hospital of UPMC Health System Pittsburgh, PA
- UPMC PAssavant Pittsburgh, PA
- UPMC St Margaret Pittsburgh, PA
- Excela Health Westmoreland Regional Hospital Greensburg, PA
Medical groups
- University of Pittsburgh Physicians (4,236 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 66
- Services billed
- 117
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 42 | 33 |
| Established patient office or other outpatient visit, 40-54 minutes | 42 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 4 payments worth $4,885 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,980 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $1,593 |
| AstraZeneca UK Limited | $930 |
| Vertex Pharmaceuticals Incorporated | $383 |
| Consulting Fee | $4,885 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Aug 21, 2025 | Consulting Fee | $1,980 |
| E.r. Squibb & Sons, L.l.c. May 29, 2025 | Consulting Fee | $1,593 |
| AstraZeneca UK Limited Jun 2, 2025 | Consulting Fee | $930 |
| Vertex Pharmaceuticals Incorporated Nov 4, 2025 | Consulting Fee | $383 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $8,506 in research payments for these studies, mostly to the institutions running them.
- Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
Cumberland Pharmaceuticals, Inc. · Active, not recruiting · NCT02682511
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.